Ensysce Biosciences implements 1-for-20 reverse stock split effective Oct 28, 2022

Ensysce Biosciences, Inc.

Reverse split ratio of 1-for-20; effective 12:01 am October 28, 2022.
No change to authorized shares, par value, or voting rights; fractional shares rounded up to whole share.
Exercise prices and shares issuable under warrants, options, and RSUs adjusted proportionally.
New CUSIP number 293602207; trading symbol ENSC remains on Nasdaq.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ensysce Biosciences, Inc.: Filed a Certificate of Amendment to effect a 1-for-20 reverse stock split (effective 2022-10-28).

Change: charter amendment
Effective: 2022-10-28

Exact text from the filing

On October 27, 2022, Ensysce Biosciences, Inc. (the “Company” or “we” or “our”) filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-twenty (1-for-20) reverse stock split (the “Reverse Stock Split”) of our common stock, par value $0.0001 (the “Common Stock”). The Reverse Stock Split will be effective as of 12:01 am on October 28, 2022 (the “Effective Time”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-029729

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.